[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity

Rhea-AI Filing Summary

Stanley R. Frankel, a director of Precision BioSciences, Inc. (DTIL), purchased 2,700 shares of the company's common stock on 09/26/2025 at a reported price of $4.97 per share. After this transaction he beneficially owned 16,778 shares. The Form 4 was signed on 09/30/2025 by an attorney-in-fact, Dario Scimeca. The filing identifies Frankel's address as c/o Precision BioSciences in Durham, North Carolina, and indicates the report was filed by one reporting person. No derivative transactions, amendments, or other securities activity are reported on this Form 4.

Positive

• Director purchase disclosed: Stanley R. Frankel acquired 2,700 shares, demonstrating a reported insider purchase.
• Complete Section 16 filing: Form 4 provides required transparency with number of shares and purchase price ($4.97).

Negative

• None.

Insights

Corporate Governance Expert

TL;DR Director Stanley Frankel made a routine open-market purchase of 2,700 shares, increasing his stake to 16,778 shares.

The transaction is a straightforward Section 16 disclosure showing a director-level acquisition at $4.97 per share. As filed, there are no related derivative transactions, no amendments, and the Form 4 was executed by an attorney-in-fact. For governance review, this is a routine insider buy disclosure that provides transparency on director holdings but contains no additional context about intent or planned future transactions.

Securities Analyst

TL;DR A director purchased a small block of shares; the filing contains no material qualifiers or derivative activity.

The purchase of 2,700 shares at $4.97 raises the director's beneficial ownership to 16,778 shares. The Form 4 conforms to Section 16 reporting requirements and was filed by one reporting person. There are no indications of larger, connected transactions or disposals on this filing. The disclosure is routine and informational for market participants tracking insider ownership changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Frankel Stanley

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW ST., SUITE A-100

(Street)

DURHAM NC 27701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/26/2025		P		2,700	A	$4.97	16,778	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Dario Scimeca, Attorney-in-Fact for Stanley R. Frankel	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Stanley R. Frankel report for DTIL?

He reported the purchase of 2,700 shares of DTIL common stock on 09/26/2025 at a reported price of $4.97 per share.

How many DTIL shares does the reporting person own after the transaction?

The Form 4 states the reporting person beneficially owned 16,778 shares following the transaction.

Who signed the Form 4 for the reporting person and when?

The filing was signed by Dario Scimeca, Attorney-in-Fact for Stanley R. Frankel on 09/30/2025.

Does this Form 4 report any derivative or option transactions for DTIL?

No. Table II for derivative securities shows no reported transactions on this Form 4.

Was this Form 4 filed by more than one reporting person?

No. The filing indicates it was filed by one reporting person.